InvestorsHub Logo
Followers 67
Posts 7755
Boards Moderated 0
Alias Born 05/10/2010

Re: jav0033 post# 332104

Monday, 11/09/2020 11:06:18 AM

Monday, November 09, 2020 11:06:18 AM

Post# of 402700
The "90% efficacy" claim is troubling. Based on what? This is a misleading claim. Because they are not releasing details, what seems to be able to be gleaned from what they are saying is that 90% of the cases of COVID-19 were in members of the control group. However, there are only 94 cases of COVID out of the 44,000 volunteers, and this, after only two months after vaccination.

Also, Pfizer's vaccine requires two doses, and the vaccine has to be stored and transported at extremely low temperatures. What are the chances that the vaccine will always be handled properly so that it is effective?

And, what are the chances that this vaccine is indeed safe and does not have longer-term side effects? Just as a recent example, the initial shingles vaccine was widely hailed as a safe and effective vaccine. Then, after a lot of people got dosed -- whoops, guess what, it is NOT safe and in some people TRIGGERED cases of shingles. (Please note: that vaccine has been withdrawn and the current one is safer -- supposedly.)

There have been many other cases of vaccines that appeared to be safe which turned out to have bad side effects over the longer term, when given to a very large population. Swine flu vaccine, anyone?

Also, they are saying that they will have enough vaccine to dose 15-20 million people in the next year. Even if this vaccine is safe and effective, and does not cause long-term side effects -- 15-20 million people vaccinated with even an optimistic 90% efficacy will NOT get the pandemic under control.

TREATMENTS will. And if you or a family member are among those who get COVID in the next year, you're going to be mighty grateful if there are good treatments available -- like, for instance, Brilacidin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News